Inhibrx Biosciences (INBX) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• Inhibrx Biosciences (NASDAQ:INBX) is set to release its Q2 2025 earnings on August 12th, with a projected loss of ($2.92) per share, following a previous loss of ($2.80) that missed analyst expectations.
• The company's market capitalization stands at $314.65 million with a stock price of $21.73, having a significant debt-to-equity ratio of 1.04 and a P/E ratio of 0.19.
• Institutional investors dominate the ownership with 82.46% of the company's shares held by institutions, including a new stake acquired by Strs Ohio.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) is expected to release its Q2 2025 earnings data before the market opens on Tuesday, August 12th. Analysts expect Inhibrx Biosciences to post earnings of ($2.92) per share for the quarter.

Inhibrx Biosciences (NASDAQ:INBX - Get Free Report) last posted its earnings results on Wednesday, May 14th. The company reported ($2.80) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.55) by ($0.25). On average, analysts expect Inhibrx Biosciences to post $105 EPS for the current fiscal year and $-12 EPS for the next fiscal year.

Inhibrx Biosciences Stock Performance

Shares of NASDAQ INBX traded up $0.30 during mid-day trading on Thursday, reaching $21.28. 9,171 shares of the company were exchanged, compared to its average volume of 105,322. The company's 50-day simple moving average is $17.94 and its 200-day simple moving average is $14.60. The company has a quick ratio of 5.12, a current ratio of 5.12 and a debt-to-equity ratio of 1.04. The stock has a market capitalization of $308.05 million, a P/E ratio of 0.18 and a beta of 0.24. Inhibrx Biosciences has a twelve month low of $10.80 and a twelve month high of $25.29.

Institutional Investors Weigh In On Inhibrx Biosciences

An institutional investor recently bought a new position in Inhibrx Biosciences stock. Strs Ohio acquired a new stake in Inhibrx Biosciences, Inc. (NASDAQ:INBX - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 1,900 shares of the company's stock, valued at approximately $27,000. Institutional investors and hedge funds own 82.46% of the company's stock.

Wall Street Analysts Forecast Growth

Separately, JMP Securities reiterated a "market perform" rating on shares of Inhibrx Biosciences in a research note on Thursday, May 15th.

About Inhibrx Biosciences

Inhibrx, Inc, a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency.